tofacitinib (Xeljanz)


Original post, click here

Generic Name: tofacitinib

Brand Name: Xeljanz

Manufacturer: Pfizer Canada Inc.

Indications: Arthritis, Psoriatic

Manufacturer Requested Reimbursement Criteria1:

For the treatment of adult patients with active psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

Submission Type: New Indication

Project Status: Pending

Call For Patient Input: June 12, 2018

Patient Input Closed: August 1, 2018

Anticipated Date: July 11, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Tags

arthritis, dermatology, musculoskeletal